Title:
【発明の名称】VLA-4のためのインヒビターとしての尿素化合物
Document Type and Number:
Japanese Patent JP2003520790
Kind Code:
A
Abstract:
A compound of formula (I) where D is a VLA-4 specificity determinant which does not impart significant IIB/IIIa activity; R41 is a group of the formula (V): U - (CH2)d - V - T wherein U is selected from oxygen, sulphur, a direct bond or -CH2O-, V is selected from nitrogen, oxygen, sulphur, S(O), S(O)2 or a direct bond, d is zero or a number from 1 to 4, and T is selected from a range of variables defined in the application; and other variables are defined in the application, or a pharmaceutically acceptable salt or in vivo hydrolysable derivative thereof. The compounds are useful in the treatment of disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor alpha4beta1. Pharmaceutical compositions and methods of use or treatment are also described and claimed.
More Like This:
Inventors:
Craig John Stone
Michael Stewart Large
Michael Stewart Large
Application Number:
JP2001553754A
Publication Date:
July 08, 2003
Filing Date:
January 17, 2001
Export Citation:
Assignee:
AstraZeneca Actie Borak
International Classes:
C07D295/08; A61K31/17; A61K31/192; A61K31/40; A61K31/445; A61K31/4453; A61K31/4465; A61K31/5375; A61P11/06; A61P19/02; A61P25/00; A61P29/00; A61P35/04; A61P37/08; A61P43/00; C07C273/00; C07C275/42; C07C317/18; C07C323/12; C07D211/22; C07D211/46; C07D211/54; C07D211/96; C07D295/092; (IPC1-7): C07C275/42; A61K31/17; A61K31/192; A61K31/40; A61K31/445; A61K31/4453; A61K31/4465; A61K31/5375; A61P11/06; A61P19/02; A61P25/00; A61P29/00; A61P35/04; A61P37/08; A61P43/00; C07C273/00; C07C317/18; C07C323/12; C07D211/46; C07D211/96; C07D295/08
Domestic Patent References:
| JP2002543060A | 2002-12-17 | |||
| JP2002521375A | 2002-07-16 | |||
| JP2002521376A | 2002-07-16 |
Foreign References:
| WO1998004913A1 | 1998-02-05 | |||
| WO1998004247A1 | 1998-02-05 |
Attorney, Agent or Firm:
Toshio Yano (3 outside)